Biotechnology Stock News
Categories
- All
- Editor's Picks
- Q&A with Gurus
- Gurus' Stock Picks
- Insider Transaction
- Earning Reports
- CEO Shareholder Letters
- Press Release
- Earnings Call Transcripts
- Podcast
Industries
- Aerospace & Defense
- Agriculture
- Asset Management
- Banks
- Beverages - Alcoholic
- Beverages - Non-Alcoholic
- Biotechnology
- Building Materials
- Business Services
- Capital Markets
- Chemicals
- Conglomerates
- Construction
- Consumer Packaged Goods
- Credit Services
- Diversified Financial Services
- Drug Manufacturers
- Education
- Farm & Heavy Construction Machinery
- Forest Products
- Furnishings, Fixtures & Appliances
- Hardware
- Healthcare Plans
- Healthcare Providers & Services
- Homebuilding & Construction
- Industrial Distribution
- Industrial Products
- Insurance
- Interactive Media
- Manufacturing - Apparel & Accessories
- Media - Diversified
- Medical Devices & Instruments
- Medical Diagnostics & Research
- Medical Distribution
- Metals & Mining
- Oil & Gas
- Other Energy Sources
- Packaging & Containers
- Personal Services
- Real Estate
- REITs
- Restaurants
- Retail - Cyclical
- Retail - Defensive
- Semiconductors
- Software
- Steel
- Telecommunication Services
- Tobacco Products
- Transportation
- Travel & Leisure
- Utilities - Independent Power Producers
- Utilities - Regulated
- Vehicles & Parts
- Waste Management
GuruFocus News Biotechnology
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Regulatory Challenges
Lexicon Pharmaceuticals Inc (LXRX) showcases progress in clinical developments and strategic partnerships, while navigating regulatory hurdles and financial pressures. Nov 13, 2024
GuruFocus News Biotechnology
Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges
Corvus Pharmaceuticals Inc (CRVS) progresses with promising trials and designations, despite reporting a significant net loss for the quarter. Nov 13, 2024
GuruFocus News Biotechnology
Voyager Therapeutics Inc (VYGR) Q3 2024 Earnings Call Highlights: Strong Cash Position and Promising Alzheimer's Program
Voyager Therapeutics Inc (VYGR) reports a robust financial runway and advances in Alzheimer's research, despite challenges in clinical trials. Nov 13, 2024
GuruFocus News Biotechnology
Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Financial Challenges
Zevra Therapeutics Inc (ZVRA) reports significant progress with Myle's launch and strategic planning, despite financial setbacks and underperformance of Aprova. Nov 13, 2024
GuruFocus News Biotechnology
Xenon Pharmaceuticals Inc (XENE) Q3 2024 Earnings Call Highlights: Strategic Advancements and Financial Resilience
Xenon Pharmaceuticals Inc (XENE) showcases robust clinical progress and a strong financial position, while navigating challenges in a competitive landscape. Nov 13, 2024
GuruFocus News Biotechnology
Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Call Highlights: Promising Clinical Trial Results and Strategic Collaborations
Clearside Biomedical Inc (CLSD) advances its wet AMD program with positive trial outcomes, while navigating financial and regulatory challenges. Nov 13, 2024
GuruFocus News Biotechnology
Lisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost Management Success
Lisata Therapeutics Inc (LSTA) reports effective cost management and promising clinical developments, despite challenges in market valuation and trial enrollments. Nov 13, 2024
GuruFocus News Biotechnology
SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements
SpringWorks Therapeutics Inc (SWTX) reports a 23% revenue increase and anticipates FDA approval for a new treatment, despite short-term challenges. Nov 13, 2024
GuruFocus News Biotechnology
Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Insights
Autolus Therapeutics PLC (AUTL) reports significant progress with FDA approval of AUCATZYL, robust financial positioning, and strategic challenges in its Q3 2024 earnings call. Nov 13, 2024
GuruFocus News Biotechnology
Mirum Pharmaceuticals Inc (MIRM) Q3 2024 Earnings Call Highlights: Record Sales Surge and Strategic Pipeline Expansion
Mirum Pharmaceuticals Inc (MIRM) reports an 89% increase in net product sales and achieves positive operating cash flow for the first time, while expanding its rare disease pipeline. Nov 13, 2024
GuruFocus News Biotechnology
Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding R&D Investments
Altimmune Inc (ALT) reports significant progress in its clinical trials and regulatory alignment, despite rising costs and strategic partnership challenges. Nov 13, 2024
GuruFocus News Biotechnology
WAVE Life Sciences Ltd (WVE) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Despite a net loss, WAVE Life Sciences Ltd (WVE) showcases promising clinical progress and a strengthened financial position to support future growth. Nov 13, 2024